促性腺激素及其受体基因变异在控制性卵巢刺激中的临床相关性:系统综述与荟萃分析
本系统综述与荟萃分析评估了促卵泡激素、促黄体生成素及其受体基因的7个多态性对控制性卵巢刺激结局的影响,纳入33项研究。FSHR rs6165 AA纯合子较GG纯合子及AG杂合子获卵数更多,刺激时间更短;FSHR rs1394205 GG纯合子及AG杂合子较AA纯合子FSH用量显著更低。作者认为特定基因型与生殖结局相关,但需进一步研究以确定其应用于药物基因组学方法。
要点
- FSHR rs6165 AA纯合子获卵数较GG纯合子及AG杂合子更多,刺激时间更短。
- FSHR rs6165 AA纯合子较GG纯合子获卵数及MII卵数更多。
- FSHR rs1394205 GG纯合子及AG杂合子较AA纯合子FSH用量显著更低。
核心结论
- 特定基因型谱与生殖结局具有临床相关性,但需进一步研究以确定其在卵巢刺激药物基因组学方法中的应用。
研究设计与样本
- 按Cochrane协作网及PRISMA指南进行的系统综述与荟萃分析,无时间限制,检索PubMed/MEDLINE、Cochrane Library、SCOPUS和EMBASE截至2017年1月前发表的研究,仅纳入同行评议期刊全文临床试验,主要结局为获卵数。
- 57项研究评估合格性,33项纳入定性与定量分析。
- 评估了7个多态性:FSHR rs6165、FSHR rs6166、FSHR rs1394205、LHB rs1800447、LHB rs1056917、LHCGR rs2293275和LHCGR rs13405728。
主要发现
- FSHR rs6165 AA纯合子获卵数多于GG纯合子及AG杂合子(5项研究,677例,WMD 1.85,95%CI 0.85-2.85,P<0.001,I²=0%;4项研究,630例,WMD 1.62,95%CI 0.28-2.95,P=0.020,I²=56%)。
- FSHR rs6165 AA纯合子刺激时间短于AG携带者(3项研究,588例,WMD -0.48,95%CI -0.87至-0.10,P=0.010,I²=44%)。
- FSHR rs6165 AA纯合子较GG纯合子获卵数更多(21项研究,2632例,WMD 0.84,95%CI 0.19-1.49,P=0.01,I²=76%),MII卵数更多(5项研究,608例,WMD 1.03,95%CI 0.01-2.05,P=0.050,I²=0%)。
- FSHR rs1394205 GG纯合子FSH用量低于AA纯合子(3项研究,411例,WMD -1294.61 IU,95%CI -593.08至-1996.14 IU,P=0.0003,I²=99%)。
- FSHR rs1394205 AG杂合子FSH用量低于AA纯合子(3项研究,367例,WMD -1014.36 IU,95%CI -364.11至-1664.61 IU,P=0.002,I²=99%)。
临床怎么用
- 作者认为这些结果支持特定基因型谱与生殖结局的临床相关性,但需进一步研究以确定其在卵巢刺激药物基因组学方法中的应用。
局限性
- 需进一步研究以确定基因型在卵巢刺激药物基因组学方法中的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genotype has been implicated in the outcome of ovarian stimulation. The analysis of patient-specific genotypes might lead to an individualized pharmacogenomic approach to controlled ovarian stimulation (COS). However, the validity of such an approach remains to be established. OBJECTIVE AND RATIONALE: To define the impact of specific genotype profiles of follicle-stimulating hormone, luteinizing hormone and their receptors (FSHR, LHR and LHCGR) on ovarian stimulation outcome. Specifically, our aim was to identify polymorphisms that could be useful in clinical practice, and those that need further clinical investigation. SEARCH METHODS: A systematic review followed by a meta-analysis was performed according to the Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines without time restriction. We searched the PubMed/MEDLINE, Cochrane Library, SCOPUS and EMBASE databases to identify all relevant studies published before January 2017. Only clinical trials published as full-text articles in peer-reviewed journals were included. The primary outcome was the number of oocytes retrieved. OUTCOMES: Fifty-seven studies were assessed for eligibility, 33 of which were included in the qualitative and quantitative analyses. Data were independently extracted using quality indicators. COS outcomes related to seven polymorphisms (FSHR [rs6165], FSHR [rs6166], FSHR [rs1394205], LHB [rs1800447], LHB [rs1056917], LHCGR [rs2293275] and LHCGR [rs13405728]) were evaluated. More oocytes were retrieved from FSHR (rs6165) AA homozygotes (five studies, 677 patients, weighted mean difference [WMD]: 1.85, 95% CI: 0.85-2.85, P < 0.001; I2 = 0%) than from GG homozygotes and AG heterozygotes (four studies, 630 patients, WMD: 1.62, 95% CI: 0.28-2.95, P = 0.020; I2 = 56%). Moreover, stimulation duration was shorter in FSHR (rs6165) AA homozygotes than in AG carriers (three studies, 588 patients, WMD -0.48, 95% CI: -0.87 to -0.10, P = 0.010, I2 = 44%). A higher number of oocytes (21 studies, 2632 patients WMD: 0.84, 95% CI: 0.19 to 1.49, P = 0.01, I2 = 76%) and metaphase II oocytes (five studies, 608 patients, WMD: 1.03, 95% CI: 0.01-2.05, P = 0.050, I2 = 0%) was observed in AA than in GG homozygote carriers. FSH consumption was significantly lower in FSHR (rs1394205) GG homozygotes (three studies, 411 patients, WMD: -1294.61 IU, 95% CI: -593.08 to -1996.14 IU, P = 0.0003, I2 = 99%) and AG heterozygotes (three studies, 367 patients, WMD: -1014.36 IU, 95% CI: -364.11 to -1664.61 IU, P = 0.002, I2 = 99%) than in AA homozygotes. WIDER IMPLICATIONS: These results support the clinical relevance of specific genotype profiles on reproductive outcome. Further studies are required to determine their application in a pharmacogenomic approach to ovarian stimulation.
引用
- Alviggi C, Conforti A, Santi D, et al. Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis. Hum Reprod Update. 2018. PMID: 29924306. doi:10.1093/humupd/dmy019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。